EXOME: Biotech • Healthcare • Life Sciences

San Diego
Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego’s Synthorx

New York
Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule
National
Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More
National
Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results

1.
KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test | Boston
2.
Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules | National
3.
Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer | San Diego
4.
Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs | New York
5.
Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego’s Synthorx | San Diego
6.
Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals | National

Learn about the Xconomists →

Bryony Winn

Bryony Winn

Chief Strategy and Innovation Officer, Blue Cross and Blue Shield of North Carolina

Digital Health Survivors & Innovative Incumbents Must Team Up for True Disruption

Rob Coppedge

Rob Coppedge

CEO of Echo Health Ventures

Partner or Die: How to Succeed Even After the Digital Health Hype Quiets Down

More Opinion, Insight, and Analysis ›

What’s Next in Neuroscience Therapies – Xconomy San Francisco Life Science Forum – Nov. 19, 2019

November 19, 2019

$2.7B

Merck/ArQule

Flexion Co-Founder, Chief Scientific Officer Neil Bodick to Retire

Replimune Taps Ex-Merrimack Exec for Chief Financial Officer Post

Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule
Frank Vinluan | New York
AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets
Melissa Fassbender | Boston
3 Takeaways From the Resurrection of Biogen’s Alzheimer’s Drug
Sarah de Crescenzo | San Diego
Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis
Sarah de Crescenzo | San Diego
FDA Puts Partial Hold on Tests of Ipsen Drug Acquired in $1B Deal
Frank Vinluan | National
Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More
Sarah de Crescenzo | National
Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results
Sarah de Crescenzo | National
FDA Rejects Enzyvant’s Regenerative Therapy for Rare Immune Disorder
Frank Vinluan | Boston
Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
Frank Vinluan | Boston

Read More Posts ›

Underwriters and Partners

Xpertise: Watch + Learn

From Our Partners · Special Report
Robert Langer reveals secrets to early-stage biotech success
Advice for funding and future transformational opportunities

From Our Editors · Special Report
2019 Biopharma Outlook – Facing an Uncertain Future
Key indicators & expert insight from industry leaders
Xconomy

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Tweets from https://twitter.com/Xconomy/lists/lifesci